Drug discovery: Leaving no stone unturned.
Katharine
K
Gammon
D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology*; D023181:Antimicrobial Cationic Peptides / Q000276:immunology; D001419:Bacteria / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D001427:Bacterial Toxins / Q000037:antagonists & inhibitors; D001428:Bacterial Vaccines; D001430:Bacteriocins / Q000494:pharmacology / Q000627:therapeutic use; D015195:Drug Design; D055808:Drug Discovery / Q000379:methods*; D004926:Escherichia coli / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D051379:Mice; D050296:Microbial Viability / Q000187:drug effects; D050997:Nanomedicine; D011161:Porifera / Q000235:genetics / Q000382:microbiology; D055502:Secondary Prevention; D013045:Species Specificity; D000198:Spectinomycin / Q000737:chemistry / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D023181:Antimicrobial Cationic Peptides; D001427:Bacterial Toxins; D001428:Bacterial Vaccines; D001430:Bacteriocins; C000588754:avidocin; D000198:Spectinomycin